Antibody–drug conjugates (ADCs) have transformed oncology and represent one of the fastest-growing therapeutic modalities in cancer drug development. Advances in antibody engineering, linker chemistry and payload design have expanded the clinical success of ADCs, leading to numerous approvals and a rapidly growing development pipeline. Yet despite these advances, predicting which patients will respond remains a major challenge.
Historically, biomarker strategies have focused on target expression. While antigen expression is essential for ADC binding, recent studies consistently show that it does not fully explain therapeutic outcome. Tumors with similar antigen expressions frequently exhibit markedly different responses, suggesting that additional biological mechanisms determine productive ADC activity.
This white paper explores how biomarker strategies for ADCs are evolving from isolated measurements toward integrated biological evidence. Rather than presenting individual technologies, it illustrates how spatially connecting drug distribution, target engagement, pharmacodynamic response, and tumor microenvironment can identify the biological bottlenecks driving sensitivity or resistance and ultimately support development decisions across preclinical and clinical programs.
Download the white paper to learn more.